Utah's Medicaid Rx drug list cuts spending

28 September 2008

The US state of Utah, which introduced a preferred prescription drug list in 2007, has reported reduced spending for its medicine-related Medicaid services in the program's first year of $546,000. However, the Utah Department of Health admitted that the amount was less than one sixth of the $2.8-million forecast saving to taxpayers.

The Department's Director, David Sundwall, blamed state legislators for the cost overrun, explaining that amendments to the scheme had allowed physicians to override the preferred drugs more easily than anticipated in the original proposal. The Salt Lake City Tribune also reported that some drugs were only added to the Medicaid list during the course of the year. Mr Sundwall said that lower administrative costs should bring $1.2 million in lower bills next fiscal year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight